Nature.com spotlights Saisei Pharma’s MAF longevity research

By AI, Created 8:16 AM UTC, May 29, 2026, /AGP/ – Saisei Hawaii said Nature.com has featured Saisei Pharma’s MAF research in a Spotlight: Nutrition article on links between nutrition and longevity. The piece highlights studies in Japan on sarcopenia, telomeres, IGF-1 and Klotho, alongside a related mouse study now available on PubMed Central.

Why it matters: - The Nature.com feature gives Saisei Pharma’s MAF research mainstream scientific visibility. - The article frames MAF as part of a broader effort to study nutrition-linked pathways tied to healthy aging, muscle health and cellular longevity. - The coverage may help customers and the wellness community understand the research behind Saisei Pharma’s MAF series food supplements.

What happened: - Saisei Hawaii said Nature.com Spotlight: Nutrition published an article titled “Exploring links between nutrition and longevity.” - The feature examines how researchers in Japan are studying whether dietary MAF may affect biological pathways associated with healthy aging. - The article highlights Saisei Pharma’s work on sarcopenia, telomeres, IGF-1 and Klotho-related longevity mechanisms. - Dr. Toshio Inui, co-founder of Saisei Pharma, said in the Nature.com article: “Historically, nutrition has been associated with longevity.”

The details: - MAF is described as an immune-related protein that helps activate macrophages, which clear dead or damaged cells and harmful pathogens. - Saisei Pharma researchers are studying whether adding MAF to the diet may influence age-related biological changes. - The Nature.com feature cites collaborations with the National Hospital Organization Kyoto Medical Center, Tokushima University, Konan University, Tottori University and Hiroshima University. - Those collaborations include preclinical and clinical studies on sarcopenia and other proteins and genes linked to aging. - Sarcopenia is an age-related condition marked by a progressive decline in muscle mass and strength. - Sarcopenia is associated with frailty and may raise the risk of falls, fractures and physical disability. - Saisei Pharma and collaborators are examining whether MAF supplementation may influence muscle atrophy factors, muscle growth factors and motor coordination. - A clinical trial in Osaka is testing whether Saisei Pharma’s MAF supplement changes circulating IGF-1 levels. - IGF-1, or insulin-like growth factor-1, is associated with muscle growth and repair. - In the Nature.com article, Dr. Inui described IGF-1 as having “a very strong, protective action against sarcopenia.” - The article also discusses telomeres, the protective caps at the ends of chromosomes that are widely studied in cellular aging. - Saisei Pharma researchers and collaborators reported in mouse studies that oral MAF slightly lengthened telomeres. - Those mouse studies also showed increased expression of telomerase-related components. - Saisei Pharma researchers are studying 161 human participants in Japan who are age 40 and older. - The human study is testing whether orally administered MAF taken for three or six months may affect telomere length. - The feature says Saisei Pharma mouse research suggests MAF may work partly by triggering overexpression of Klotho in the blood, brain and kidneys. - Researchers are also exploring whether similar Klotho-related effects may appear in humans.

Between the lines: - The Nature.com coverage connects Saisei Pharma’s supplement research to areas that are already central to longevity science. - The company is using a mix of preclinical and human studies to build a narrative around nutrition, immunity and aging biology. - The article also places the research in the context of Japan’s aging population and Okinawa’s status as a Blue Zone. - Saisei Hawaii’s role is partly commercial and partly educational, linking customers to supplements and public research materials.

What’s next: - Saisei Pharma’s 161-person study may provide new human data on whether oral MAF affects telomere length. - The Osaka trial may clarify whether MAF changes IGF-1 levels in people. - Further research will likely continue on telomeres, Klotho-associated pathways, sarcopenia and immune function. - The company says its broader goal is to advance longevity, rejuvenation and healthy aging through nutrition-based research.

The bottom line: - Nature.com’s Spotlight gives Saisei Pharma’s MAF program a high-profile platform, but the core claims still rest on ongoing research into whether the supplement can influence aging-related biology in humans.

The details: - Saisei’s degalactosylated whey protein, or D-WP, is also known as MAF. - A related Scientific Reports study titled “Oral intake of degalactosylated whey protein increases peripheral blood telomere length in young and aged mice” provides a foundation for the broader MAF research program. - The study found that oral intake of D-WP significantly increased peripheral blood telomere length in young mice after four weeks. - In aged mice, shortened telomere length was significantly restored to a level comparable with young mice. - The study also reported increased mRNA expression of telomerase-related components, including TERT and TERC. - Saisei’s MAF series is based on patented Japanese technology developed within the Saisei group. - Saisei Hawaii said the company helps customers access Saisei Pharma’s MAF series food supplements and publicly available research and educational information. - Saisei Hawaii was established in Honolulu in 2018 and serves customers in the United States and Canada. - Saisei Pharma is headquartered in Osaka and develops patented food-based technologies focused on longevity, healthy aging, immune function, cognitive decline and muscle health. - The full Nature.com Spotlight: Nutrition article is available on Nature.com. - The related Scientific Reports study is available on PubMed Central.